CLINICAL_TRIALS
trial_result
· 2022-11-01
Clinical Trial Update: Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2 [Phase 2]
Summary
Phase II study of RC48-ADC for salivary gland tumors expressing HER2 is underway, with status currently unknown.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Peking Union Medical College Hospital | Conditions: Salivary Gland Tumors | Phase 2 | Status: UNKNOWN